1. Home
  2. XEL vs ARGX Comparison

XEL vs ARGX Comparison

Compare XEL & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XEL
  • ARGX
  • Stock Information
  • Founded
  • XEL 1909
  • ARGX 2008
  • Country
  • XEL United States
  • ARGX Netherlands
  • Employees
  • XEL N/A
  • ARGX N/A
  • Industry
  • XEL Power Generation
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • XEL Utilities
  • ARGX Health Care
  • Exchange
  • XEL Nasdaq
  • ARGX Nasdaq
  • Market Cap
  • XEL 39.2B
  • ARGX 33.0B
  • IPO Year
  • XEL N/A
  • ARGX 2017
  • Fundamental
  • Price
  • XEL $72.66
  • ARGX $591.99
  • Analyst Decision
  • XEL Buy
  • ARGX Strong Buy
  • Analyst Count
  • XEL 12
  • ARGX 17
  • Target Price
  • XEL $75.92
  • ARGX $730.07
  • AVG Volume (30 Days)
  • XEL 2.8M
  • ARGX 450.9K
  • Earning Date
  • XEL 07-31-2025
  • ARGX 07-31-2025
  • Dividend Yield
  • XEL 3.14%
  • ARGX N/A
  • EPS Growth
  • XEL 2.18
  • ARGX N/A
  • EPS
  • XEL 3.40
  • ARGX 15.94
  • Revenue
  • XEL $13,698,000,000.00
  • ARGX $2,643,062,000.00
  • Revenue This Year
  • XEL $13.83
  • ARGX $61.64
  • Revenue Next Year
  • XEL $6.48
  • ARGX $32.00
  • P/E Ratio
  • XEL $21.38
  • ARGX $34.02
  • Revenue Growth
  • XEL N/A
  • ARGX 82.13
  • 52 Week Low
  • XEL $56.42
  • ARGX $471.97
  • 52 Week High
  • XEL $73.56
  • ARGX $678.21
  • Technical
  • Relative Strength Index (RSI)
  • XEL 67.52
  • ARGX 63.19
  • Support Level
  • XEL $68.01
  • ARGX $560.91
  • Resistance Level
  • XEL $73.56
  • ARGX $575.48
  • Average True Range (ATR)
  • XEL 1.14
  • ARGX 12.76
  • MACD
  • XEL 0.51
  • ARGX 4.44
  • Stochastic Oscillator
  • XEL 87.14
  • ARGX 95.80

About XEL Xcel Energy Inc.

Xcel Energy manages utilities serving 3.8 million electric customers and 2.2 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan; Public Service Company of Colorado; and Southwestern Public Service Company, which serves customers in Texas and New Mexico. It is one of the largest renewable energy suppliers in the US, with more than half of its electricity sales coming from carbon-free energy.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: